Use of Sortilin as Biomarker for Affective/Mood Disorders

Patent metadata

Field	Value
Publication number	US-2016349276-A1
Application number	US-201515117967-A
Country	US
Kind code	A1
Filing date	Feb 6, 2015
Priority date	Feb 12, 2014
Publication date	Dec 1, 2016
Grant date	—

Abstract

The present invention relates to the use of Sortilin as a biomarker. In particular, Sortilin is useful as a biomarker for affective disorders. In one aspect of the invention Sortilin may be used to aid the diagnosing and to monitor disease progression in bipolar disorder and unipolar depression by measuring Sortilin levels. The invention further provides methods for informing the choice of treatment of bipolar disorder and unipolar depression by determining the levels of Sortilin.

First claim

1 . (canceled)

2 . A method to diagnose or monitor bipolar or unipolar disorder in a subject, wherein said method comprises:
(a) causing a psychiatric examination of said subject to be conducted in order to diagnose the presence of such disorder or monitor its progression; and (b) contacting a sample of tissue or fluid from said subject with an anti-Sortilin antibody under conditions sufficient to permit said anti-Sortilin antibody to immunospecifically and detectably bind said epitope of Sortilin if present in said sample at a concentration of between approximately 8.5 ng/ml and 47 ng/ml; and (c) determining the concentration of said epitope of Sortilin in said sample by measuring said detected binding.

3 . A method for treating a bipolar or unipolar disorder in a subject suffering from bipolar disorder, wherein said method comprises:
(a) causing a therapeutically effective amount of a mood-stabilizing agent or atypical antipsychotic to be administered to said subject; (b) contacting sample of tissue or fluid from said subject with an anti-Sortilin antibody under conditions sufficient to permit said anti-Sortilin antibody to immunospecifically and detectably bind said epitope of Sortilin if present in said sample at a concentration of between approximately 8.5 ng/ml and 47 ng/ml; and (c) determining the concentration of said epitope of Sortilin in said sample by measuring said detected binding.

4 . An immunoassay kit for quantifying the level of Sortilin in a sample of tissue or fluid from a subject, wherein said kit comprises an anti-Sortilin antibody that is capable of immunospecifically binding an epitope of Sortilin (SEQ ID NO:1), and wherein said anti-Sortilin antibody is detectably-labeled, or said kit additionally comprises a detectable second antibody capable of immunospecifically binding a molecular complex of said anti-Sortilin antibody bound to said epitope of Sortilin, wherein said immunoassay is capable of detecting said epitope of Sortilin if present in said sample at a concentration of between approximately 8.5 ng/ml and 47 ng/ml.

5 - 6 . (canceled)

7 . The method according to claim 2 , wherein said sample is a fluid sample.

8 . The method according to claim 7 , wherein said fluid sample is a blood, plasma or serum sample.

9 - 12 . (canceled)

13 . The method according to claim 3 , wherein said mood-stabilizing agent or atypical antipsychotic is lithium carbonate, an anticonvulsant medicine or antipsychotic medicine, an antidepressant medicine, or a combination thereof.

14 . The method according to claim 13 , wherein said mood-stabilizing agent or atypical antipsychotic is an anticonvulsant medicine or antipsychotic medicine and is selected from the group consisting of: valproate, carbamazepine, lamotrigine, aripiprazole, olanzapine, quetiapine and risperidone.

15 - 26 . (canceled)

27 . The method according to claim 2 , wherein said disorder is bipolar disorder.

28 . The method according to claim 2 , wherein said disorder is unipolar disorder.

29 . The method according to claim 3 , wherein said disorder is bipolar disorder.

30 . The method according to claim 3 , wherein said disorder is unipolar disorder.

31 . The method according to claim 3 , wherein said sample is a fluid sample.

32 . The method according to claim 31 , wherein said fluid sample is a blood, plasma or serum sample.

33 . The immunoassay kit according to claim 4 , wherein said anti-Sortilin antibody is detectably-labeled.

34 . The immunoassay kit according to claim 4 , wherein said kit comprises said detectable second antibody capable of immunospecifically binding a molecular complex of said anti-Sortilin antibody bound to said epitope of Sortilin.

35 . The immunoassay kit according to claim 4 , wherein said kit is capable of detecting said epitope of Sortilin in a fluid sample.

36 . The immunoassay kit according to claim 4 , wherein said fluid sample a blood, plasma or serum sample.

Assignees

• H Lundbeck As

Inventors

• Jepsen Jesper Lundhede
• Nykjaer Anders
• Mors Niels Peter Ole
• Petersen Claus Munck
• Østergaard Søren Dinesen
• Glerup Simon

Classifications

• A61P25/24

  Antidepressants · CPC title

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• G01N33/6896 Primary

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N2800/304

  Mood disorders, e.g. bipolar, depression · CPC title